Equities

MediciNova Inc

MediciNova Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)215.00
  • Today's Change1.00 / 0.47%
  • Shares traded27.40k
  • 1 Year change-31.31%
  • Beta0.8353
Data delayed at least 20 minutes, as of Jun 14 2024 07:00 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

MediciNova, Inc. is a biopharmaceutical company. The Company is focused on developing therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States market. It is focused on its development activities on MN-166 (ibudilast) for neurological and other disorders, such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction (e.g., methamphetamine dependence, opioid dependence, and alcohol dependence), prevention of acute respiratory distress syndrome (ARDS), and Long COVID, and MN-001 (tipelukast) for fibrotic and other diseases, such as nonalcoholic fatty liver disease (NAFLD) and idiopathic pulmonary fibrosis (IPF). The Company's pipeline also includes MN-221 (bedoradrine) for the treatment of acute exacerbation of asthma and MN-029 (denibulin) for solid tumor cancers.

  • Revenue in USD (TTM)1.00m
  • Net income in USD-8.41m
  • Incorporated2000
  • Employees13.00
  • Location
    MediciNova IncSUITE 650, 4275 EXECUTIVE SQUARELA JOLLA 92037United StatesUSA
  • Phone+1 (858) 373-1500
  • Fax+1 (858) 404-0048
  • Websitehttps://medicinova.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
CellSeed Inc193.68m-892.21m8.24bn35.00--3.83--42.57-29.71-29.716.4764.750.0881.637.625,533,600.00-40.53-49.69-43.83-54.5556.5863.66-460.67-428.6219.14--0.0669--50.39-28.62-11.43--80.73--
Kohjin Bio Co Ltd4.77bn384.98m8.81bn157.0022.462.5921.621.8576.7776.77951.17666.48----------------39.44--8.07--1.14--0.4249--0.5715---53.61------
TMS Co Ltd0.00-960.04m8.83bn14.00--2.55-----25.89-25.890.0085.770.00----0.00-26.14---26.78-------------2,219.420.00-------11.51------
CanBas Co Ltd (Parent)0.00-1.09bn8.99bn12.00--3.00-----64.47-64.470.00166.100.00----0.00-43.91-65.86-45.99-79.11-------1,094.10----0.00-------45.41------
Tsubota Laboratory Inc673.53m-641.32m9.03bn10.00--6.60--13.41-25.15-25.1526.4253.450.27112.0437.74---25.82---36.41--3.17---95.22--2.31-489.860.0788---29.45---811.14------
Wakamoto Pharmaceutical Co Ltd7.74bn108.96m9.16bn292.0083.780.75993.721.183.143.14222.97346.510.49712.092.57--0.70-2.280.8046-2.6446.5251.001.41-3.973.85--0.0083---10.65-6.35-21.19--4.93--
K Pharma Inc500.00m-221.98m9.42bn15.00--3.28--18.85-18.94-18.9443.04247.430.20954.49--33,333,330.00-9.30---9.83--91.00---44.40--42.60--0.00------166.34------
Linical Co Ltd12.31bn338.27m9.92bn759.0026.771.1011.580.80614.9814.98544.93364.600.6837--3.59--1.884.013.156.3330.7030.992.755.48----0.260350.10-1.671.70-66.32-9.86-10.184.56
AnGes Inc249.94m-6.35bn10.30bn145.00--0.3616--41.22-32.62-32.621.29124.450.00770.08624.771,723,752.00-19.47-28.50-23.06-33.1439.8539.42-2,540.59-6,726.820.9124--0.0139--128.13-24.1749.45--12.11--
Medicinova Inc157.02m-1.32bn10.55bn13.00--1.12--67.19-26.92-26.923.20191.550.0149----12,078,460.00-12.55-15.36-13.06-15.90-----840.85-1,182.54----0.00------39.08--15.87--
KOEI CHEMICAL COMPANY, LIMITED19.43bn299.18m11.25bn387.0037.520.51454.820.578961.1761.173,971.904,460.940.49571.663.80--0.76593.150.9973.9427.1725.241.555.850.6907115.660.320743.884.441.19-56.72-20.82-3.2910.76
Medinet Co Ltd711.82m-1.40bn11.54bn98.00--2.07--16.21-6.00-6.003.0321.730.12411.343.787,263,510.00-24.31-21.05-25.48-22.4715.2528.75-196.06-135.4020.08--0.00--4.40-7.90-14.66---17.67--
3-D Matrix Ltd4.59bn-255.51m11.90bn108.00--32.12--2.59-3.56-3.5662.614.330.78360.51345.16---4.36-42.10-5.76-55.6067.2653.95-5.57-96.031.91--0.922--98.3069.4189.55---30.34--
Nano Mrna Co Ltd135.51m-780.00m12.18bn17.00--3.56--89.87-11.10-11.101.9348.610.02559.029.66---14.37-24.16-15.59-25.1781.8884.69-575.61-600.709.17--0.2448---32.98-22.8840.50------
ReproCell Inc2.43bn-31.42m12.37bn92.00--1.48163.055.10-0.3465-0.346528.3493.450.27885.415.60---0.3609-7.35-0.3932-8.0046.1939.83-1.29-27.1610.54-------17.8317.3989.71--13.27--
Chordia Therapeutics Inc-100.00bn-100.00bn12.58bn21.00--3.40----------56.42----------------------------0.00------112.55------
Data as of Jun 14 2024. Currency figures normalised to MediciNova Inc's reporting currency: Japanese Yen JPY
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.